These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

24 related articles for article (PubMed ID: 3096624)

  • 1. Effects of calcium disodium versenate (CaNa2EDTA) chelation in moderate childhood lead poisoning.
    Markowitz ME; Bijur PE; Ruff H; Rosen JF
    Pediatrics; 1993 Aug; 92(2):265-71. PubMed ID: 8337028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of lead and arsenic poisoning in anuric patients - a case report and narrative review of the literature.
    Hsiao CY; Gresham C; Marshall MR
    BMC Nephrol; 2019 Oct; 20(1):374. PubMed ID: 31623560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chelation for autism spectrum disorder (ASD).
    James S; Stevenson SW; Silove N; Williams K
    Cochrane Database Syst Rev; 2015 May; 5(5):CD010766. PubMed ID: 26114777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of calcium-EDTA as an inhibitor for metallo-β-lactamase in a mouse model of Pseudomonas aeruginosa pneumonia.
    Aoki N; Ishii Y; Tateda K; Saga T; Kimura S; Kikuchi Y; Kobayashi T; Tanabe Y; Tsukada H; Gejyo F; Yamaguchi K
    Antimicrob Agents Chemother; 2010 Nov; 54(11):4582-8. PubMed ID: 20713659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic abnormalities in lead toxic children: public health implications.
    Rosen JF
    Bull N Y Acad Med; 1989 Dec; 65(10):1067-84; discussion 1085-8. PubMed ID: 2698246
    [No Abstract]   [Full Text] [Related]  

  • 6. L-line x-ray fluorescence of cortical bone lead compared with the CaNa2EDTA test in lead-toxic children: public health implications.
    Rosen JF; Markowitz ME; Bijur PE; Jenks ST; Wielopolski L; Kalef-Ezra JA; Slatkin DN
    Proc Natl Acad Sci U S A; 1989 Jan; 86(2):685-9. PubMed ID: 2492111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequential measurements of bone lead content by L X-ray fluorescence in CaNa2EDTA-treated lead-toxic children.
    Rosen JF; Markowitz ME; Bijur PE; Jenks ST; Wielopolski L; Kalef-Ezra JA; Slatkin DN
    Environ Health Perspect; 1991 Feb; 91():57-62. PubMed ID: 1904023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential measurements of bone lead content by L X-ray fluorescence in CaNa2EDTA-treated lead-toxic children.
    Rosen JF; Markowitz ME; Bijur PE; Jenks ST; Wielopolski L; Kalef-Ezra JA; Slatkin DN
    Environ Health Perspect; 1991 Jun; 93():271-7. PubMed ID: 1773798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Usefulness of biomarkers of exposure to inorganic mercury, lead, or cadmium in controlling occupational and environmental risks of nephrotoxicity.
    Roels HA; Hoet P; Lison D
    Ren Fail; 1999; 21(3-4):251-62. PubMed ID: 10416202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of CaNa2EDTA and chelation of lead in renal failure.
    Osterloh J; Becker CE
    Clin Pharmacol Ther; 1986 Dec; 40(6):686-93. PubMed ID: 3096624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of ceftazidime in patients with renal insufficiency.
    Welage LS; Schultz RW; Schentag JJ
    Antimicrob Agents Chemother; 1984 Feb; 25(2):201-4. PubMed ID: 6370127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of famotidine, a new H2-receptor antagonist, in relation to renal function.
    Takabatake T; Ohta H; Maekawa M; Yamamoto Y; Ishida Y; Hara H; Nakamura S; Ushiogi Y; Kawabata M; Hashimoto N
    Eur J Clin Pharmacol; 1985; 28(3):327-31. PubMed ID: 2861096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of intravenous cefetamet and oral cefetamet pivoxil in patients with renal insufficiency.
    Kneer J; Tam YK; Blouin RA; Frey FJ; Keller E; Stathakis C; Luginbuehl B; Stoeckel K
    Antimicrob Agents Chemother; 1989 Nov; 33(11):1952-7. PubMed ID: 2610506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disposition of guanadrel in subjects with normal and impaired renal function.
    Halstenson CE; Opsahl JA; Abraham PA; Schwenk MH; Andreadis NA; Antal EJ; Matzke GR
    J Clin Pharmacol; 1989 Feb; 29(2):128-32. PubMed ID: 2715368
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.